Optic Neuropathy | 2020 Pipeline Review with Analysis by Indication, Stage of Development, Mechanism of Action, Route of Administration and Molecule Type
DUBLIN, March 31, 2020 /PRNewswire/ --The "Optic Neuropathy - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This pipeline guide, Optic Neuropathy - Pipeline Review, H1 2020 provides comprehensive information on the therapeutics under development for Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 2, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
-- The pipeline guide provides a snapshot of the global therapeutic
landscape of Optic Neuropathy (Ophthalmology).
-- The pipeline guide reviews pipeline therapeutics for Optic Neuropathy
(Ophthalmology) by companies and universities/research institutes based
on information derived from company and industry-specific sources.
-- The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and undisclosed
stages.
-- The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing and
collaboration details, R&D brief, MoA & other developmental activities.
-- The pipeline guide reviews key companies involved in Optic Neuropathy
(Ophthalmology) therapeutics and enlists all their major and minor
projects.
-- The pipeline guide evaluates Optic Neuropathy (Ophthalmology)
therapeutics based on mechanism of action (MoA), drug target, route of
administration (RoA) and molecule type.
-- The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
-- The pipeline guide reviews latest news related to pipeline therapeutics
for Optic Neuropathy (Ophthalmology).
Reasons to Buy
-- Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-- Recognize emerging players with potentially strong product portfolio and
create effective counter-strategies to gain competitive advantage.
-- Find and recognize significant and varied types of therapeutics under
development for Optic Neuropathy (Ophthalmology).
-- Classify potential new clients or partners in the target demographic.
-- Develop tactical initiatives by understanding the focus areas of leading
companies.
-- Plan mergers and acquisitions meritoriously by identifying key players
and it's most promising pipeline therapeutics.
-- Formulate corrective measures for pipeline projects by understanding
Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication
therapeutics.
-- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
-- Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Key Topics Covered
1. Introduction
2. Report Coverage
3. Optic Neuropathy - Overview
4. Optic Neuropathy - Therapeutics Development
5. Pipeline Overview
6. Pipeline by Companies
7. Pipeline by Universities/Institutes
8. Products under Development by Companies
9. Products under Development by Universities/Institutes
10. Optic Neuropathy - Therapeutics Assessment
11. Assessment by Target
12. Assessment by Mechanism of Action
13. Assessment by Route of Administration
14. Assessment by Molecule Type
15. Optic Neuropathy - Companies Involved in Therapeutics Development
16. Optic Neuropathy - Drug Profiles
17. Optic Neuropathy - Dormant Projects
18. Optic Neuropathy - Discontinued Products
19. Optic Neuropathy - Product Development Milestones
Featured News & Press Releases
-- May 14, 2019: Regenera announces publication of RPh201 Phase 2a study
data for the treatment of NAION in the Journal of Neuro-Ophthalmology
-- Oct 22, 2018: Quark Pharmaceuticals to present data on Optic Neuropathy
drug candidate QPI-1007 at AAO 2018 Annual Meeting
-- Aug 06, 2018: Regenera Pharma enrols first patient in Phase lll trial of
RPh201
-- Nov 13, 2017: RiboQuark Pharmaceutical Technology Announces Enrollment
of The First Ever Patient in China for a Pivotal Clinical Trial with a
siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular
Neuroprotectant QPI-1007
-- Oct 14, 2016: Quark Pharmaceuticals Launches EyeActNow.com to Promote
NAION Study Steps-Up Recruitment for Phase II/III Research on Stroke of
the Eye'
-- Sep 19, 2016: Quark Pharmaceuticals to provide an overview on siRNA
candidate QPI-1007
-- Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007
Ocular Neuroprotectant
-- Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III
Study of QPI-1007 in Rare Eye Disease in India
-- Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase
III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications
-- Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient
Recruitment for Global Pivotal Study of QPI-1007 in NAION
-- Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in
patients with chronic Ischemic Optic Neuropathy
-- Apr 30, 2011: Regenera Pharma received the final report of its safety
study in minipigs and is moving to human studies
-- Jun 24, 2010: Quark Pharmaceuticals Announces Presentation of its siRNA
Drug Candidate QPI-1007 at Glaucoma & Retinopathies 2010
Companies Mentioned
-- Allergan PLC
-- Antoxis Ltd.
-- Neurizon Pharma GBR
-- PharmatrophiX Inc.
-- Quark Pharmaceuticals Inc.
-- Recursion Pharmaceuticals Inc.
-- Regenera Pharma Ltd.
-- Regeneron Pharmaceuticals Inc.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/u816qx
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
